Discover 3 UK Penny Stocks With Market Caps Over £80M

The London stock market has recently faced challenges, with the FTSE 100 index closing lower amid concerns over weak trade data from China, highlighting global economic uncertainties. In such a climate, investors might consider exploring penny stocks—traditionally smaller or newer companies—that can offer unique opportunities for growth and diversification. Despite being an older term, penny stocks remain relevant today as they often present a mix of affordability and potential when backed by strong financials.

Here's a peek at a few of the choices from the screener.

Alumasc Group (AIM:ALU)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: The Alumasc Group plc, with a market cap of £88.36 million, manufactures and sells building products and solutions across the United Kingdom, Europe, North America, the Middle East, the Far East, and internationally.

Operations: The company's revenue is primarily derived from three segments: Water Management (£46.59 million), Building Envelope (£41.79 million), and Housebuilding Products (£18.74 million).

Market Cap: £88.36M

The Alumasc Group plc, with a market cap of £88.36 million, is actively pursuing acquisitions to bolster its strategic growth despite recent executive changes. The company reported full-year sales of £107.12 million, down from the previous year, with net income decreasing to £7.31 million. While its operating cash flow adequately covers debt obligations and interest payments are well covered by EBIT, the company's profit margins have declined from last year. Despite experiencing negative earnings growth recently, Alumasc's short-term assets comfortably cover both short and long-term liabilities, suggesting financial stability amidst ongoing strategic shifts.

• Take a closer look at Alumasc Group's potential here in our financial health report.
• Understand Alumasc Group's earnings outlook by examining our growth report.

NIOX Group (AIM:NIOX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: NIOX Group Plc specializes in the design, development, and commercialization of medical devices for diagnosing, monitoring, and managing asthma and COPD globally, with a market cap of £286.19 million.

Operations: NIOX Group Plc has not reported any specific revenue segments.

Market Cap: £286.19M

NIOX Group Plc, with a market cap of £286.19 million, has demonstrated significant earnings growth of 105.9% over the past year, surpassing its five-year average of 23.4% annually. Despite a stable weekly volatility at 4%, NIOX's Return on Equity remains low at 10.4%. The company is debt-free and its short-term assets (£30.9M) exceed both short and long-term liabilities, indicating solid financial health. Recent earnings reports show stable net income year-over-year despite a slight sales decline to £24 million for the first half of 2026, suggesting consistent performance in the medical devices sector amidst industry challenges.

• Click to explore a detailed breakdown of our findings in NIOX Group's financial health report.
• Learn about NIOX Group's future growth trajectory here.

S4 Capital (LSE:SFOR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: S4 Capital plc, with a market cap of £304.86 million, offers digital advertising, marketing, and technology services across the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Operations: The company generates revenue from two main segments: Marketing Services (£682.6 million) and Technology Services (£55.8 million).

Market Cap: £304.86M

S4 Capital plc, with a market cap of £304.86 million, operates in digital advertising and marketing services. Despite being unprofitable, it maintains a positive cash flow and has more than three years of cash runway. The company's net debt to equity ratio is satisfactory at 12.4%, but its share price has been highly volatile recently. Recent leadership changes include the appointment of Nirvik Singh as CEO EMEA Marketing Services to drive regional growth, while strategic partnerships like the AI-powered platform with Watts Law Firm LLP highlight its technological advancements. S4 also initiated an inaugural interim dividend payment despite ongoing losses.

• Click here and access our complete financial health analysis report to understand the dynamics of S4 Capital.
• Explore S4 Capital's analyst forecasts in our growth report.

Key Takeaways

• Get an in-depth perspective on all 263 UK Penny Stocks by using our screener here.
• Contemplating Other Strategies? The end of cancer? These 35 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com